Centaurus Financial Inc. Acquires 5,364 Shares of Eli Lilly and Company (NYSE:LLY)

Centaurus Financial Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 87.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,463 shares of the company’s stock after acquiring an additional 5,364 shares during the quarter. Centaurus Financial Inc.’s holdings in Eli Lilly and Company were worth $10,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Wealth Dimensions Group Ltd. increased its stake in Eli Lilly and Company by 2.5% during the 3rd quarter. Wealth Dimensions Group Ltd. now owns 3,258 shares of the company’s stock valued at $2,886,000 after purchasing an additional 81 shares in the last quarter. Alpha DNA Investment Management LLC bought a new stake in Eli Lilly and Company during the 3rd quarter valued at about $285,000. Sompo Asset Management Co. Ltd. increased its stake in Eli Lilly and Company by 2.8% during the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 3,980 shares of the company’s stock valued at $3,526,000 after purchasing an additional 110 shares in the last quarter. MGB Wealth Management LLC increased its stake in Eli Lilly and Company by 11.2% during the 3rd quarter. MGB Wealth Management LLC now owns 1,142 shares of the company’s stock valued at $1,012,000 after purchasing an additional 115 shares in the last quarter. Finally, Penserra Capital Management LLC increased its stake in Eli Lilly and Company by 45.2% during the 3rd quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock valued at $770,000 after purchasing an additional 271 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on LLY shares. Barclays reduced their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.3 %

Shares of LLY opened at $748.01 on Friday. The company’s fifty day moving average is $865.01 and its 200 day moving average is $869.65. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The stock has a market capitalization of $710.10 billion, a PE ratio of 80.87, a P/E/G ratio of 2.84 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 13.2 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.